Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Bronchogenic

Explore clinical trials studying Carcinoma, Bronchogenic. Study availability and eligibility vary by location and protocol.

5,277 public trials 1,202 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Bronchogenic trial results

Recruiting

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

NCT06223711

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Extensive-stage Small-cell Lung Cancer, +8 more
Locations
  • University Hospital Augsburg, Radiation Oncology Augsburg, Bavaria, Germany
  • University Hospital Erlangen, Radiation Oncology Erlangen, Bavaria, Germany
  • University Hospital Regensburg, Clinic and Polyclinic for Radiotherapy Regensburg, Bavaria, Germany
  • Kliniken Maria Hilf Mönchengladbach, North Rhine-Westphalia, Germany
View Trial Details
Recruiting

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

NCT06225804

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Precision NextGen Oncology Beverly Hills, California, United States
  • Anhui Chest Hospital Hefei, Anhui, China
  • Fujian Cancer Hospital Fuzhou, Fujian, China
  • The first Affiliated Hospital of Xi'an Jiaotong University Xi'an, Harbin, China
View all 14 locations
View Trial Details
Recruiting

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

NCT06053099

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +11 more
Locations
  • Angers - CHU Angers, France
  • Bayonne - CH Bayonne, France
  • Boulogne - Ambroise Paré Boulogne, France
  • Lyon - URCOT Bron, France
View all 36 locations
View Trial Details
Recruiting

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT05085028

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Royal Bournemouth Hospital Bournemouth, United Kingdom
  • Royal Sussex County Hospital Brighton, United Kingdom
  • Bristol Haematology and Oncology Centre Bristol, United Kingdom
  • Queen's Hospital Burton-on-Trent, United Kingdom
View all 37 locations
View Trial Details

Related conditions